Table 4. Univariable Analysis of Cancer-Specific Survival.
| Variable | No. | Cancer-Specific Survival, No. (%)a | Univariable P Valueb | |
|---|---|---|---|---|
| 3 y | 5 y | |||
| All patients | 202 | 155 (76.9) | 109 (53.9) | NA |
| Sex | ||||
| Male | 118 | 87 (74.0) | 63 (53.5) | .38 |
| Female | 84 | 68 (80.8) | 46 (54.6) | |
| Age at hepatic resection, y | ||||
| ≥60 | 74 | 56 (75.3) | 34 (46.6) | .15 |
| <60 | 128 | 99 (77.6) | 76 (59.7) | |
| Primary Tumor | ||||
| Location | ||||
| Rectum | 41 | 32 (78.4) | 20 (49.4) | .74 |
| Colon | 161 | 123 (76.6) | 89 (55.1) | |
| T category | ||||
| T3/T4 | 167 | 127 (75.8) | 85 (50.9) | .31 |
| T1/T2 | 35 | 29 (82.4) | 24 (67.4) | |
| Lymph node metastasesc | ||||
| Yes | 125 | 89 (71.1) | 62 (49.9) | .048 |
| No | 77 | 67 (87.4) | 47 (61.4) | |
| Prehepatic resection chemotherapy | ||||
| Yes | 168 | 128 (76.0) | 88 (52.5) | .49 |
| No | 34 | 28 (82.8) | 22 (65.1) | |
| Hepatic Resection | ||||
| Operative time, min | ||||
| >180 | 125 | 100 (80.3) | 69 (55.4) | .34 |
| ≤180 | 77 | 55 (71.0) | 40 (52.2) | |
| Estimated blood loss, mL | ||||
| ≥500 | 37 | 30 (82.4) | 19 (51.6) | .96 |
| <500 | 165 | 124 (75.4) | 91 (55.3) | |
| Red blood cell transfusion | ||||
| Yes | 17 | 14 (82.4) | 9 (51.8) | .76 |
| No | 185 | 141 (76.1) | 101 (54.4) | |
| Surgical procedure | ||||
| Major hepatic resection | 99 | 76 (76.6) | 50 (51.0) | .27 |
| Minor hepatic resection | 103 | 79 (76.9) | 59 (57.3) | |
| Carcinoembryonic antigen at hepatic resection, ng/mL | ||||
| ≥5 | 84 | 62 (74.4) | 48 (57.2) | .93 |
| <5 | 118 | 93 (78.7) | 61 (52.1) | |
| Timing of diagnosis of primary tumor and CLMsc | ||||
| Synchronous | 148 | 113 (76.1) | 78 (52.5) | .89 |
| Metachronous | 54 | 43 (79.1) | 31 (58.2) | |
| No. of CLMsc | ||||
| Multiple | 113 | 79 (69.9) | 52 (46.1) | .005 |
| Solitary | 89 | 77 (86.7) | 58 (65.2) | |
| Largest metastasis, cmc | ||||
| ≥3 | 86 | 58 (67.7) | 43 (50.1) | .09 |
| <3 | 116 | 97 (84.0) | 66 (57.1) | |
| Residual tumor | ||||
| R1 | 17 | 12 (72.6) | 5 (30.3) | .19 |
| R0 | 185 | 143 (77.3) | 103 (55.8) | |
| RAS statusc | ||||
| Mutant | 73 | 47 (64.1) | 31 (42.8) | .003 |
| Wild type | 129 | 109 (84.2) | 79 (60.9) | |
| Major morbidity with Clavien-Dindo grade ≥IIIac | ||||
| Yes | 51 | 32 (63.7) | 15 (29.2) | .002 |
| No | 151 | 122 (81.1) | 92 (60.8) | |
| RLI after hepatic resectionc | ||||
| Grade ≥2 | 50 | 26 (52.7) | 10 (20.7) | <.001 |
| Grade ≤1 | 152 | 129 (84.8) | 97 (63.7) | |
| Posthepatic resection chemotherapy | ||||
| Yes | 184 | 140 (76.1) | 101 (54.7) | .85 |
| No | 18 | 16 (87.2) | 9 (47.7) | |
Abbreviations: CLMs, colorectal liver metastases; NA, not applicable; RLI, remnant liver ischemia.
SI conversion factor: To convert carcinoembryonic antigen level to micrograms per liter, multiply by 1.0.
a
By Kaplan-Meier method.
b
By log-rank test.
c
Variables entered into the Cox proportional hazards regression model.